B Galling1,2,3, J A Vernon2, A K Pagsberg4,5, A Wadhwa2, E Grudnikoff6, A J Seidman7, M Tsoy-Podosenin8, M Poyurovsky9,10, J M Kane2,3,11, C U Correll1,2,3,11. 1. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany. 2. The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA. 3. Hofstra Northwell School of Medicine, Hofstra University, Hempstead, NY, USA. 4. Child and Adolescent Mental Health Center, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark. 5. Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. 6. South Oaks Hospital, Amityville, NY, USA. 7. Department of Psychology, Iowa State University, Ames, IA, USA. 8. Department of Psychiatry, St John's Episcopal Hospital, New York, NY, USA. 9. Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel. 10. Tirat Carmel Mental Health Center, tirat Carmel, Israel. 11. The Feinstein Institute for Medical Research, Manhasset, NY, USA.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of antidepressant augmentation of antipsychotics in schizophrenia. METHODS: Systematic literature search (PubMed/MEDLINE/PsycINFO/Cochrane Library) from database inception until 10/10/2017 for randomized, double-blind, efficacy-focused trials comparing adjunctive antidepressants vs. placebo in schizophrenia. RESULTS: In a random-effects meta-analysis (studies = 42, n = 1934, duration = 10.1 ± 8.1 weeks), antidepressant augmentation outperformed placebo regarding total symptom reduction [standardized mean difference (SMD) = -0.37, 95% confidence interval (CI) = -0.57 to -0.17, P < 0.001], driven by negative (SMD = -0.25, 95% CI = -0.44-0.06, P = 0.010), but not positive (P = 0.190) or general (P = 0.089) symptom reduction. Superiority regarding negative symptoms was confirmed in studies augmenting first-generation antipsychotics (FGAs) (SMD = -0.42, 95% CI = -0.77, -0.07, P = 0.019), but not second-generation antipsychotics (P = 0.144). Uniquely, superiority in total symptom reduction by NaSSAs (SMD = -0.71, 95% CI = -1.21, -0.20, P = 0.006) was not driven by negative (P = 0.438), but by positive symptom reduction (SMD = -0.43, 95% CI = -0.77, -0.09, P = 0.012). Antidepressants did not improve depressive symptoms more than placebo (P = 0.185). Except for more dry mouth [risk ratio (RR) = 1.57, 95% CI = 1.04-2.36, P = 0.03], antidepressant augmentation was not associated with more adverse events or all-cause/specific-cause discontinuation. CONCLUSIONS: For schizophrenia patients on stable antipsychotic treatment, adjunctive antidepressants are effective for total and particularly negative symptom reduction. However, effects are small-to-medium, differ across antidepressants, and negative symptom improvement seems restricted to the augmentation of FGAs.
OBJECTIVE: To evaluate the efficacy and safety of antidepressant augmentation of antipsychotics in schizophrenia. METHODS: Systematic literature search (PubMed/MEDLINE/PsycINFO/Cochrane Library) from database inception until 10/10/2017 for randomized, double-blind, efficacy-focused trials comparing adjunctive antidepressants vs. placebo in schizophrenia. RESULTS: In a random-effects meta-analysis (studies = 42, n = 1934, duration = 10.1 ± 8.1 weeks), antidepressant augmentation outperformed placebo regarding total symptom reduction [standardized mean difference (SMD) = -0.37, 95% confidence interval (CI) = -0.57 to -0.17, P < 0.001], driven by negative (SMD = -0.25, 95% CI = -0.44-0.06, P = 0.010), but not positive (P = 0.190) or general (P = 0.089) symptom reduction. Superiority regarding negative symptoms was confirmed in studies augmenting first-generation antipsychotics (FGAs) (SMD = -0.42, 95% CI = -0.77, -0.07, P = 0.019), but not second-generation antipsychotics (P = 0.144). Uniquely, superiority in total symptom reduction by NaSSAs (SMD = -0.71, 95% CI = -1.21, -0.20, P = 0.006) was not driven by negative (P = 0.438), but by positive symptom reduction (SMD = -0.43, 95% CI = -0.77, -0.09, P = 0.012). Antidepressants did not improve depressive symptoms more than placebo (P = 0.185). Except for more dry mouth [risk ratio (RR) = 1.57, 95% CI = 1.04-2.36, P = 0.03], antidepressant augmentation was not associated with more adverse events or all-cause/specific-cause discontinuation. CONCLUSIONS: For schizophreniapatients on stable antipsychotic treatment, adjunctive antidepressants are effective for total and particularly negative symptom reduction. However, effects are small-to-medium, differ across antidepressants, and negative symptom improvement seems restricted to the augmentation of FGAs.
Authors: Elias Wagner; John M Kane; Christoph U Correll; Oliver Howes; Dan Siskind; William G Honer; Jimmy Lee; Peter Falkai; Thomas Schneider-Axmann; Alkomiet Hasan Journal: Schizophr Bull Date: 2020-12-01 Impact factor: 9.306
Authors: Pei Shang; Ada Man-Choi Ho; Maximilian Tufvesson-Alm; Daniel R Lindberg; Caroline W Grant; Funda Orhan; Feride Eren; Maria Bhat; Göran Engberg; Lilly Schwieler; Helena Fatouros-Bergman; Sophie Imbeault; Ryan M Iverson; Surendra Dasari; Fredrik Piehl; Simon Cervenka; Carl M Sellgren; Sophie Erhardt; Doo-Sup Choi Journal: Transl Psychiatry Date: 2022-06-03 Impact factor: 7.989
Authors: Steven G Potkin; John M Kane; Christoph U Correll; Jean-Pierre Lindenmayer; Ofer Agid; Stephen R Marder; Mark Olfson; Oliver D Howes Journal: NPJ Schizophr Date: 2020-01-07
Authors: S Galderisi; S Kaiser; I Bitter; M Nordentoft; A Mucci; M Sabé; G M Giordano; M Ø Nielsen; L B Glenthøj; P Pezzella; P Falkai; S Dollfus; W Gaebel Journal: Eur Psychiatry Date: 2021-03-17 Impact factor: 5.361